{
    "organizations": [],
    "uuid": "bc044e6d2af786975318d49dbc42132c71b4cd26",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pfizers-biosimilar-retacrit-approv/brief-pfizers-biosimilar-retacrit-approved-by-u-s-fda-idUSFWN1SM1E2",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Pfizer Inc:\n* PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA\n* PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT\n* PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-16T03:05:00.000+03:00",
    "crawled": "2018-05-16T18:51:09.060+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "biosimilar",
        "epoetin",
        "approved",
        "fda",
        "pfizer",
        "inc",
        "retacrit",
        "expected",
        "available",
        "significant",
        "discount",
        "current",
        "wholesaler",
        "acquisition",
        "cost",
        "epogen",
        "procrit",
        "pfizer",
        "inc",
        "entered",
        "agreement",
        "vifor",
        "pharma",
        "inc",
        "commercialization",
        "retacrit",
        "certain",
        "channel",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}